On the 19th June 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorisation for daratumumab for patients with high-risk smouldering myeloma. Daratumumab is a monoclonal antibody marketed by Johnson & Johnson as Darzalex®. This medicine has been designed to recognise and bind to the CD38 protein, which is found on the surface…
During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival and quality of life. Dr. Sundar Jagannath discusses the long-term remission and survival for relapsed/refractory patients after treatment with ciltacabtagene…
To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 24 June at 17:00 CET. The session will be led by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at…
The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma. Myeloma Patients Europe (MPE) will be attending the congress to…
On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is with bortezomib (a proteasome inhibitor) plus the steroid dexamethasone (BVd) in patients who have received at least one prior therapy.…
Prothena, the pharmaceutical company that produce the AL amyloidosis drug birtamimab, have announced that the Phase III AFFIRM-AL clinical trial failed to meet its primary endpoint – i.e., the main result being measured in the trial to determine whether the treatment was effective. This means that the trial failed to demonstrate that newly diagnosed AL…
Myeloma Patients Europe (MPE) will host a webinar on “Living well with AL amyloidosis” on Thursday, 5 June 2025 from 17:00 – 18:00 CEST. Aimed at AL amyloidosis patients and patient advocates, the webinar will feature presentations on supportive care for patients. Prof. Dr. Monique Minnema, Haematologist at the University Medical Centre Utrecht, will focus…
It is with great sadness that we share the news of the passing of our friend, colleague, and fellow patient advocate, Reidar Nordby. With his passing, Myeloma Patients Europe (MPE) has lost not only a dear friend but also a valued Board member since 2023, who contributed to the growth and development of our organisation.…
